About Bicara Therapeutics Inc. Common Stock
https://www.bicara.comBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
CEO
Claire Mazumdar Clemon
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 97
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:6.96M
Value:$125.35M
SIREN, L.L.C.
Shares:5.22M
Value:$94.01M
VESTAL POINT CAPITAL, LP
Shares:5.1M
Value:$91.9M
Summary
Showing Top 3 of 119
About Bicara Therapeutics Inc. Common Stock
https://www.bicara.comBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $40.68M ▲ | $-36.33M ▼ | 0% | $-0.67 ▼ | $-36.23M ▼ |
| Q2-2025 | $0 | $32.02M ▼ | $-27.39M ▲ | 0% | $-0.5 ▲ | $-32M ▲ |
| Q1-2025 | $0 | $41.79M ▲ | $-36.85M ▼ | 0% | $-0.68 ▼ | $-41.77M ▼ |
| Q4-2024 | $0 | $26.64M ▲ | $-20.96M ▼ | 0% | $-0.38 ▼ | $-26.62M ▼ |
| Q3-2024 | $0 | $20.63M | $-17.48M | 0% | $-0.32 | $-20.61M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $290.17M ▼ | $424.69M ▼ | $21.91M ▲ | $402.78M ▼ |
| Q2-2025 | $436.61M ▼ | $453.59M ▼ | $18.39M ▼ | $435.2M ▼ |
| Q1-2025 | $462.06M ▼ | $478.08M ▼ | $19.12M ▼ | $458.96M ▼ |
| Q4-2024 | $489.71M ▼ | $569.2M ▲ | $77.32M ▲ | $491.88M ▼ |
| Q3-2024 | $520.76M | $524.17M | $14.62M | $509.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-36.33M ▼ | $-29.25M ▼ | $-236.12M ▼ | $436K ▲ | $-264.93M ▼ | $-29.29M ▼ |
| Q2-2025 | $-27.39M ▲ | $-25.59M ▲ | $0 | $135K ▼ | $-25.46M ▲ | $-25.59M ▲ |
| Q1-2025 | $-36.85M ▼ | $-28.11M ▲ | $0 ▲ | $460K ▲ | $-27.65M ▲ | $-28.11M ▲ |
| Q4-2024 | $-20.96M ▼ | $-30.03M ▼ | $-40K ▼ | $-975K ▼ | $-31.05M ▼ | $-30.07M ▼ |
| Q3-2024 | $-17.48M | $-17.22M | $-8K | $334.13M | $316.9M | $-17.23M |
CEO
Claire Mazumdar Clemon
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 97
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:6.96M
Value:$125.35M
SIREN, L.L.C.
Shares:5.22M
Value:$94.01M
VESTAL POINT CAPITAL, LP
Shares:5.1M
Value:$91.9M
Summary
Showing Top 3 of 119